A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma
Phase 1 Terminated
4 enrolled
Connect® MM- The Multiple Myeloma Disease Registry
Terminated
3,011 enrolled
CPIT001
Phase 1/2 Terminated
46 enrolled 13 charts
BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma
Phase 1 Terminated
96 enrolled
Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older
Phase 2 Terminated
63 enrolled 11 charts
Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Relapsed or Refractory Multiple Myeloma
Phase NA Terminated
1 enrolled
Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib
Terminated
50 enrolled
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
Phase 1 Terminated
35 enrolled 10 charts
Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant
Phase 2 Terminated
13 enrolled 9 charts
A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Phase 1/2 Terminated
200 enrolled
iinnovate-3
Phase 1/2 Terminated
15 enrolled 12 charts
iinnovate-1
Phase 1/2 Terminated
272 enrolled 67 charts
iinnovate-2
Phase 1 Terminated
15 enrolled 15 charts
RE-NEZ-SENS
Phase NA Terminated
5 enrolled
PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma
Phase 2 Terminated
146 enrolled
AlloRelapseMM
Phase 3 Terminated
28 enrolled
A Study of WVT078 in Patients With Multiple Myeloma (MM)
Phase 1 Terminated
56 enrolled
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
Phase 1/2 Terminated
130 enrolled
CARTIFAN-1
Phase 2 Terminated
123 enrolled
TOMMY
Phase NA Terminated
13 enrolled 10 charts
DC15-MM-01
Phase 1 Terminated
4 enrolled
Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
Phase 1 Terminated
6 enrolled
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma
Phase 1/2 Terminated
15 enrolled 15 charts
LIMBER
Phase 1/2 Terminated
22 enrolled 28 charts
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Phase 1/2 Terminated
137 enrolled 31 charts
Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma
Phase 2 Terminated
23 enrolled
VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)
Phase 1 Terminated
37 enrolled
A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Phase 1 Terminated
174 enrolled
Tasquinimod for the Treatment of Relapsed or Refractory Myeloma
Phase 1 Terminated
30 enrolled
AMBROBiMM
Terminated
3 enrolled
KarMMa-7
Phase 1/2 Terminated
21 enrolled
Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission
Phase 2 Terminated
24 enrolled 8 charts
Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma
Phase 2 Terminated
17 enrolled 9 charts
Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant
Phase 1 Terminated
18 enrolled
ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals
Phase NA Terminated
2,117 enrolled 6 charts
PROACT
Phase 2 Terminated
49 enrolled 12 charts
ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
Phase 1 Terminated
1 enrolled
Noninvasive Detection and Assessment of Therapy Response in Multiple Myeloma Using Whole-Body MRI
Phase NA Terminated
21 enrolled
BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Terminated
24 enrolled
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Terminated
141 enrolled 46 charts
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Phase 2 Terminated
31 enrolled 18 charts
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
Phase 1 Terminated
55 enrolled
CART-38 in Adult AML and MM Patients
Phase 1 Terminated
11 enrolled
A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
Phase 1 Terminated
13 enrolled 10 charts
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
Phase 1 Terminated
5 enrolled
A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)
Phase 1/2 Terminated
32 enrolled
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Phase 2 Terminated
150 enrolled
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
Phase 1/2 Terminated
8 enrolled 8 charts
A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma
Phase 1/2 Terminated
40 enrolled
Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma
Phase 1 Terminated
5 enrolled